What’s New for Biologics | FDA

What’s New for Biologics | FDA

Use of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I/II); Guidance for Industry

Posted: 2/5/2020

2/5/2020	Use of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I/II); Guidance for Industry
2/4/2020	Complete List of Licensed Products and Establishments
2/4/2020	Complete List of Substantially Equivalent 510(k) Device Applications
2/4/2020	Complete List of Currently Approved Premarket Approvals (PMAs)
2/4/2020	Complete List of Currently Approved NDA and ANDA Application Submissions
2/4/2020	Important Information for Blood Establishments Regarding the Novel Coronavirus Outbreak
2/3/2020	Facilitating End-to-End Development of Individualized Therapeutics
1/31/2020	January 31, 2020 Approval Letter - PALFORZIA
1/31/2020	January 31, 2020 Approval Letter - AUDENZ
1/31/2020	BK190429 - HemoMix 4 (Basic version) and HemoMix 4 (Internal optional RFID installed version)
1/30/2020	Clinical Review - Agriflu
1/30/2020	Statistical Review - Agriflu
1/30/2020	Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components; Draft Guidance for Industry
1/29/2020	January 28, 2020 Approval Letter - Agriflu
1/28/2020	Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Draft Guidance for Industry
1/28/2020	Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry
1/28/2020	Human Gene Therapy for Retinal Disorders; Guidance for Industry
1/28/2020	Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up; Guidance for Industry
1/28/2020	Human Gene Therapy for Rare Diseases; Guidance for Industry
1/28/2020	Human Gene Therapy for Hemophilia; Guidance for Industry
1/28/2020	Long Term Follow-Up After Administration of Human Gene Therapy Products; Guidance for Industry
1/24/2020	January 22, 2020 Approval Letter - PROCLEIX WNV ASSAY
1/24/2020	January 23, 2020 Approval Letter - Afluria and Afluria Quadrivalent
1/23/2020	January 22, 2020 Approval Letter - DENGVAXIA
1/22/2020	BK190439 - MATCH IT! DNA (version 1.3)
1/22/2020	2019 Biological Device Application Approvals
1/22/2020	2019 Biological License Application Supplement Noteworthy Approvals
1/22/2020	2019 Biological License Application Approvals
1/17/2020	Vaccines and Related Biological Products Advisory Committee March 4, 2020 Meeting Announcement
1/15/2020	December 19, 2019 Summary Basis for Regulatory Action - ERVEBO
1/13/2020	CBER Vacancy: Physician, Division of Epidemiology (DE)
1/10/2020	Use of Fecal Microbiota for Transplantation (FMT) to Treat Clostridium difficile Infection Not Responsive to Standard Therapies – Transcript
1/10/2020	January 8, 2020 Approval Letter - GRASTEK
1/9/2020	CBER-Regulated Products: Current Shortages
1/7/2020	CBER Vacancy: Senior Staff Fellow – Allergic Diseases